180 Life Sciences granted listing compliance extension by Nasdaq

180 Life Sciences received notice from Nasdaq that the Hearings Panel has determined to grant the company’s request to continue its listing on Nasdaq subject to the company meeting certain conditions, including filing on or before July 31, a public disclosure describing the transactions undertaken by the company to achieve compliance with Nasdaq’s continued listing rules and demonstrate long-term compliance with the Equity Rule and providing an indication of its equity following those transactions. The company is currently out of compliance with the Listing Rule which requires listed issuers to maintain minimum stockholders’ equity of $2.5M and does not meet any of the alternative standards.